IL156941A0 - Polymer conjugates of neublastin and methods of using same - Google Patents

Polymer conjugates of neublastin and methods of using same

Info

Publication number
IL156941A0
IL156941A0 IL15694102A IL15694102A IL156941A0 IL 156941 A0 IL156941 A0 IL 156941A0 IL 15694102 A IL15694102 A IL 15694102A IL 15694102 A IL15694102 A IL 15694102A IL 156941 A0 IL156941 A0 IL 156941A0
Authority
IL
Israel
Prior art keywords
neublastin
methods
same
polymer conjugates
conjugates
Prior art date
Application number
IL15694102A
Other languages
English (en)
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of IL156941A0 publication Critical patent/IL156941A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
IL15694102A 2001-02-01 2002-01-25 Polymer conjugates of neublastin and methods of using same IL156941A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26607101P 2001-02-01 2001-02-01
PCT/US2002/002319 WO2002060929A2 (en) 2001-02-01 2002-01-25 Polymer conjugates of neublastin and methods of using same

Publications (1)

Publication Number Publication Date
IL156941A0 true IL156941A0 (en) 2004-02-08

Family

ID=23013042

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15694102A IL156941A0 (en) 2001-02-01 2002-01-25 Polymer conjugates of neublastin and methods of using same
IL156941A IL156941A (en) 2001-02-01 2003-07-15 Noblastine polymer couplings and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL156941A IL156941A (en) 2001-02-01 2003-07-15 Noblastine polymer couplings and methods of use

Country Status (36)

Country Link
EP (2) EP1355936B1 (ko)
JP (2) JP4259868B2 (ko)
KR (2) KR100960063B1 (ko)
CN (1) CN1500095B (ko)
AR (1) AR035077A1 (ko)
AT (1) ATE365748T1 (ko)
AU (1) AU2002247037B2 (ko)
BG (1) BG66393B1 (ko)
BR (1) BR0206852A (ko)
CA (1) CA2436407C (ko)
CY (1) CY1106886T1 (ko)
CZ (1) CZ20032080A3 (ko)
DE (1) DE60220879T2 (ko)
DK (1) DK1355936T3 (ko)
EA (1) EA009771B1 (ko)
EE (1) EE05537B1 (ko)
ES (1) ES2289091T3 (ko)
GE (1) GEP20063916B (ko)
HK (1) HK1057759A1 (ko)
HU (1) HU228973B1 (ko)
IL (2) IL156941A0 (ko)
IS (1) IS2867B (ko)
MX (1) MXPA03006805A (ko)
MY (1) MY143685A (ko)
NO (1) NO332150B1 (ko)
NZ (1) NZ527863A (ko)
PL (1) PL211162B1 (ko)
PT (1) PT1355936E (ko)
RS (1) RS50857B (ko)
SG (1) SG149685A1 (ko)
SI (1) SI1355936T1 (ko)
SK (1) SK288123B6 (ko)
TR (1) TR200301208T2 (ko)
UA (2) UA82983C2 (ko)
WO (1) WO2002060929A2 (ko)
ZA (1) ZA200305733B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03006805A (es) * 2001-02-01 2003-11-13 Biogen Inc Conjugados de polimero de neublastina y metodos de uso de los mismos.
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
ES2374971T3 (es) * 2001-03-28 2012-02-23 Biogen Idec Ma Inc. Uso de polipéptidos de neublastina para el tratamiento del dolor neuropático.
CN101700401B (zh) * 2002-01-18 2013-08-14 比奥根艾迪克Ma公司 具有用于共轭生物活性化合物的部分的聚亚烷基二醇
ATE478891T1 (de) * 2003-01-31 2010-09-15 Biogen Idec Inc Neublastin-mutanten
EP1897552B1 (en) 2003-04-18 2009-06-17 Biogen Idec MA Inc. Polymer-conjugated glycosylated neublastin
DK1636260T3 (da) 2003-06-10 2009-06-22 Biogen Idec Inc Forbedret udskillelse af Neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
EP1784203B1 (en) 2004-08-19 2010-06-30 Biogen Idec MA Inc. Refolding transforming growth factor beta family proteins
KR20110126732A (ko) * 2004-08-19 2011-11-23 바이오겐 아이덱 엠에이 인코포레이티드 뉴블라스틴 변형체
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
WO2008031612A1 (en) 2006-09-15 2008-03-20 Creabilis Therapeutics S.P.A. Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
JP5583005B2 (ja) 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法
ES2637423T5 (es) * 2011-11-02 2022-03-17 Hoffmann La Roche Cromatografía de sobrecarga y elución
RU2488635C1 (ru) * 2012-03-22 2013-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития Способ получения рекомбинантного антиангиогенного полипептида

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472178B1 (en) * 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
AU2354600A (en) * 1998-12-09 2000-06-26 Amgen, Inc. Grnf4 a neurotrophic factor
MXPA03006805A (es) * 2001-02-01 2003-11-13 Biogen Inc Conjugados de polimero de neublastina y metodos de uso de los mismos.

Also Published As

Publication number Publication date
ZA200305733B (en) 2005-02-23
HUP0500637A2 (hu) 2005-09-28
MXPA03006805A (es) 2003-11-13
KR20080098662A (ko) 2008-11-11
UA82983C2 (ru) 2008-06-10
NO20033441D0 (no) 2003-08-01
SK9712003A3 (en) 2004-01-08
EE05537B1 (et) 2012-04-16
DE60220879D1 (de) 2007-08-09
EP1355936B1 (en) 2007-06-27
NO20033441L (no) 2003-10-01
GEP20063916B (en) 2006-09-11
HU228973B1 (en) 2013-07-29
WO2002060929A2 (en) 2002-08-08
PL372101A1 (en) 2005-07-11
KR100872807B1 (ko) 2008-12-09
CN1500095A (zh) 2004-05-26
HUP0500637A3 (en) 2010-01-28
BG66393B1 (bg) 2013-11-29
IL156941A (en) 2008-11-03
ES2289091T3 (es) 2008-02-01
JP4423338B2 (ja) 2010-03-03
SK288123B6 (sk) 2013-09-03
JP4259868B2 (ja) 2009-04-30
KR100960063B1 (ko) 2010-05-31
KR20030074766A (ko) 2003-09-19
DK1355936T3 (da) 2007-10-29
UA100967C2 (ru) 2013-02-25
AU2002247037B2 (en) 2007-08-16
PT1355936E (pt) 2007-09-28
EA200300852A1 (ru) 2004-06-24
IS2867B (is) 2014-02-15
SI1355936T1 (sl) 2007-12-31
CZ20032080A3 (cs) 2003-10-15
SG149685A1 (en) 2009-02-27
CN1500095B (zh) 2010-06-16
EE200300355A (et) 2003-10-15
EP1862475A1 (en) 2007-12-05
JP2009039135A (ja) 2009-02-26
CA2436407C (en) 2011-08-30
CA2436407A1 (en) 2002-08-08
JP2005503763A (ja) 2005-02-10
MY143685A (en) 2011-06-30
NO332150B1 (no) 2012-07-09
WO2002060929A3 (en) 2003-03-06
HK1057759A1 (en) 2004-04-16
AR035077A1 (es) 2004-04-14
NZ527863A (en) 2006-09-29
IS6879A (is) 2003-07-17
DE60220879T2 (de) 2008-03-06
BG108111A (bg) 2004-12-30
PL211162B1 (pl) 2012-04-30
EA009771B1 (ru) 2008-04-28
EP1355936A2 (en) 2003-10-29
YU61003A (sh) 2006-05-25
RS50857B (sr) 2010-08-31
ATE365748T1 (de) 2007-07-15
TR200301208T2 (tr) 2005-05-23
CY1106886T1 (el) 2012-09-26
BR0206852A (pt) 2005-05-03

Similar Documents

Publication Publication Date Title
AU2002320058A1 (en) Magnetic-nanoparticle conjugates and methods of use
PL358335A1 (en) Polyglutamic acid-camptothecin conjugates and methods of preparation
EP1440680A4 (en) COSMETIC POLYMER COMPOSITION AND COSMETIC ARTICLES
AU2001285020A1 (en) P97-active agent conjugates and their methods of use
IL161255A0 (en) Gentle-acting skin-disinfectants and hydroalcoholic gel formulations
AU2002357119A8 (en) Mitocidal compositions and methods
IL157993A0 (en) Molecular conjugates for use in cancer treatment and methods for the preparation thereof
HK1068555A1 (en) New formulations and use thereof
ZA200305733B (en) Polymer conjugates of neublastin and methods of using same
EP1494662A4 (en) TNP-470 POLYMER CONJUGATES AND USE THEREOF
IL146842A0 (en) Polymer conjugates of hedgehog proteins and uses
EP1507793A4 (en) NEUTROKIN ALPHA AND NEUTROKIN ALPHA SPLICE VERSION
GB0121148D0 (en) Polymers and their use
EP1370240A4 (en) NEUROPROTECTOR FORMULATIONS AND METHOD
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
AU2002357748A8 (en) Osteopontin-related compositions and methods
IL162083A0 (en) Catheter composition and uses thereof
EP1402892A4 (en) ANTI-INFLAMMATORY AND ANTITUSSIVE COMPOSITIONS
AU2002359869A8 (en) Pak5-related compositions and methods
EP1421101A4 (en) P-GLYCOPROTEINS AND THEIR USES
GB0200843D0 (en) Benzodioxinopyrroles their preparation and use
AUPR326501A0 (en) Guide post and foot member
AU2002345562A1 (en) Human tachykinin-related splice variants and compositions thereof
GB0103620D0 (en) Sterile composition and its preparation
AUPR274901A0 (en) Novel therapeutic molecular variants and uses thereof - IV